Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of CX11 tablets in patients with type 2 diabetes mellitus
2025-524514-28-00Phase 2Authorised
- Sponsor
- CORXEL Pharmaceuticals
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of VCT220 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by CORXEL Pharmaceuticals. Primary endpoint: Change in HbA1c from baseline. Planned start May 2026; status: authorised.
02
Drugs
VCT220
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-524514-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524514-28-00.